ALBO News and Press, Albireo Pharma Inc. From 01/24/23

NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ...

NEW YORK, NY / ACCESSWIRE / January 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Malvern Bancorp, Inc. (NASDAQ:MLVF)'s...

Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...

NEW YORK, NY / ACCESSWIRE / January 12, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ:CINC)'s ...

Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma ( NASDAQ: ALBO ) in reaction to its deal to be acquired by France's Ipsen. Ipsen on Monday said it would buy ALBO through a tender offer of $42/share for an estimated consideration of ~$952M ...

Summary Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia. Other younger pipeline assets for orphan diseases w...

The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are acquisition deals, clinica...

Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) is acquiring Albireo ( NASDAQ: ALBO ) in deal worth about $952M plus one contingent value right (CVR) per share to bolster its rare disease portfolio with treatments for pediatric liver diseases. Albireo's lead drug is Bylvay (odevixib...

Summary ALBO has one approved indication and one more filed for a label expansion. The company has begun a slow revenue stream and has decent cash. A small opportunity presents itself in the company's measured but steady growth. For further details see: Alb...